CARCINOMA, NON-SMALL-CELL LUNG

This study tested whether adding a new drug called cabozantinib to an existing lung cancer drug (erlotinib) could help patients whose cancer had started growing again after initially responding to erlotinib alone. The trial involved 92 adults with advanced non-small cell lung can…

This study tested the safety and effectiveness of two drugs, dabrafenib and trametinib, given together to Chinese patients with advanced non-small cell lung cancer that has a specific genetic change called BRAF V600E. The goal was to see if this combination could shrink tumors an…

This early-stage study aimed to find a safe dose and understand how the body processes a new experimental drug called boserolimab. It involved 182 adults with advanced cancers, including lung and breast cancer, who had run out of standard treatment options. Researchers tested bos…

This study tested whether adding an experimental drug called LY2875358 to the standard treatment erlotinib works better than erlotinib alone for advanced lung cancer. It involved 168 patients whose cancer had spread and who had a specific genetic mutation. All patients started wi…

This study monitored 923 Korean patients with a specific type of lung cancer who were already prescribed the drug Tagrisso (osimertinib) by their doctors. The goal was to see how safe and effective the drug is in everyday, real-world use, not in a controlled trial. Researchers tr…

This early-stage study tested a combination of two immunotherapy drugs (BI 754111 and BI 754091) in adults with advanced solid tumors, including non-small cell lung cancer. The first goal was to find the safest highest dose. The second goal was to see if this combination could sh…

This early-stage study tested a new approach for hard-to-treat cancers that had spread or didn't respond to standard treatments. Researchers collected a patient's own natural killer (NK) immune cells, grew more of them in a lab, and then gave them back after using a drug (bortezo…

This large, completed Phase 3 trial tested whether a new immunotherapy drug (cemiplimab) works better than standard platinum-based chemotherapy as the first treatment for patients with advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have high levels of a ma…

This study tested a combination of two drugs, SHR-1210 and apatinib, for people with advanced non-small cell lung cancer whose cancer had grown after standard chemotherapy. The main goals were to see how safe the combination was and how well it worked to shrink tumors. It involve…

This study tested the safety and how the body processes an experimental drug called SGN-B6A in Chinese patients with advanced solid tumors. It involved a small group of 6 participants who had cancers like lung, head and neck, or stomach cancer that had stopped responding to stand…

This study tested a combination of three drugs—an immunotherapy (durvalumab) plus two chemotherapies (doxorubicin and ifosfamide)—in patients with a rare and aggressive form of non-small cell lung cancer called pulmonary sarcomatoid carcinoma (PSC). The main goal was to see if th…

This study tested if giving targeted radiation to several tumor sites before starting standard chemotherapy and immunotherapy could help people with advanced lung cancer live longer without their cancer getting worse. It involved 50 patients whose cancer had spread and who were e…

This early-stage study tested a new drug, TAK-676, combined with an existing immunotherapy (pembrolizumab) after a short course of radiation. It involved 34 adults with advanced lung cancer, triple-negative breast cancer, or head and neck cancer that had stopped responding to sta…

This study tested a drug called lorlatinib for Chinese patients with an advanced form of lung cancer (ALK-positive NSCLC) that had spread and worsened despite treatment with other targeted drugs. The goal was to see if lorlatinib could shrink tumors and control the disease. The t…

This study tested several different immunotherapy combinations for people with advanced non-small cell lung cancer that has spread. It involved 314 patients who were either newly diagnosed or whose cancer had progressed after previous treatment. The goal was to find which combina…

This study tested a combination of two drugs, bevacizumab and a double dose of icotinib, as a first treatment for people with advanced non-squamous non-small cell lung cancer (NSCLC) who have a specific genetic change called an EGFR L858R mutation. The main goal was to see if thi…

This study tested whether combining two drugs (atezolizumab and cabozantinib) works better than standard chemotherapy (docetaxel) for people with advanced non-small cell lung cancer that has spread and worsened despite prior treatments. It involved 366 patients and aimed to see i…

This study tested whether adding new experimental drugs to an existing immunotherapy (pembrolizumab) could better control advanced non-small cell lung cancer in patients who had not yet received any treatment for their metastatic disease. It involved 102 participants whose cancer…